Personalis Asset Turnover 2018-2024 | PSNL
Personalis asset turnover from 2018 to 2024. Asset turnover can be defined as the amount of sales or revenues generated per dollar of assets. The asset turnover ratio is an indicator of the efficiency with which a company is deploying its assets.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.445B | $0.085B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $19.196B | 6.94 |
| Dr Reddy's Laboratories (RDY) | India | $11.186B | 20.30 |
| BridgeBio Pharma (BBIO) | United States | $6.488B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $1.775B | 14.41 |
| Bausch Health Cos (BHC) | Canada | $1.663B | 1.22 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.145B | 7.63 |
| Taysha Gene Therapies (TSHA) | United States | $0.437B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.093B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.022B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.005B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |